Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE)
Phase of Trial: Phase I
Latest Information Update: 10 May 2017
At a glance
- Drugs Baltaleucel-T (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease; Lymphoproliferative disorders; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms PREVALE
- 01 Mar 2017 Planned primary completion date changed from 1 Feb 2019 to 16 Apr 2019.
- 01 Mar 2017 Status changed from not yet recruiting to recruiting.
- 28 Nov 2016 New trial record